Korean Market
EXCH
Ilyang Pharmaceutical
★

Ilyang Pharmaceutical Discloses Corporate Governance Report: Only 7 of 15 Core Indicators Compliant (46.7%), Highlighting Need for Governance Improvement and Enhanced Shareholder Protection

 
OWNR
Ilyang Pharmaceutical
★

Ilyang Pharmaceutical Non-Registered Executive Jeong Yeon-chan Acquires 1,050 Shares via Open Market, Stake Remains 0.01%... Limited Impact on Shareholder Value

 
OWNR
Ilyang Pharmaceutical
★

Ilyang Pharmaceutical Non-Registered Director Song Hwa-jun Acquires 2,030 Shares via Open Market... Minority Stake Increase at 0.01%, Limited Impact on Stock Price

 
PERI
Ilyang Pharmaceutical
★

Ilyang Pharm Q1: Operating Loss but Net Profit Surges on One-Time Dividend

 
EXCH
Ilyang Pharmaceutical
★

Il-Yang Pharmaceutical Invests 17.6 Billion KRW in Chinese Subsidiary for Production Base

 
EXCH
Ilyang Pharmaceutical
★

Ilyang Pharmaceutical Calls 55th Regular Shareholders' Meeting (2026.03.26)

 
EXCH
Ilyang Pharmaceutical
★★

FY2025 Consolidated Operating Profit Plunges 53% on One-time Costs

 
EXCH
Ilyang Pharmaceutical
★

Cash Dividend Decision (Common 155 won, Preferred 180 won)

 
EXCH
Ilyang Pharmaceutical
★

Ilyang Pharmaceutical Discloses 2025 CP Performance and 2026 Plan